TRENTON, N.J. (AP) — A project to speed development of cancer-fighting drugs that harness the immune system has academic and drug industry researchers collaborating and sharing their findings like never before.
Experimental tailor-made vaccines targeting melanoma patients' individual genetic mutations have given encouraging preliminary results, researchers have said. The clinical test on three patients with this form of aggressive skin cancer in an advanced stage is unprecedented in the United States. The vaccines appear to boost the number and diversity of T-cells, which are key to the human immune system and attack tumors, researchers said in a report published Thursday in the journal Science. Melanoma accounts for around five percent of all new cancer cases diagnosed in the United States, but that proportion is rising.